Synaptogenix to present at sachs 5th annual neuroscience innovation forum

New york , march 22, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that dr. daniel alkon, the company's president and chief scientific officer, will present a "spotlight showcase" of synaptogenix under the title "regenerative therapeutics" on tuesday, march 22nd at 8am et. "recently reported consolidated results of synaptogenix phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric severe impairment battery (sib) scores, over baseline, in a placebo-controlled publication on bryostatin for advanced ad patients (thompson, tuchman, and alkon, journal alzheimer's disease).
SNPX Ratings Summary
SNPX Quant Ranking